Table 2.
Univariate analysis between clinicopathological characteristics and recurrence/RCR time.
| Recurrence | RCR time | |||
|---|---|---|---|---|
| OR (95%CI) | P | OR (95%CI) | P | |
| Age (year) | 1.0 (0.9, 1.1) | 0.689 | -0.1 (-0.2, 0.1) | 0.510 |
| BMI (kg/m2) | 1.0 (0.9, 1.1) | 0.679 | 0.1 (-0.1, 0.3) | 0.220 |
| CA125 (U/mL) | 1.0 (1.0, 1.0) | 0.266 | 0.0 (-0.0, 0.0) | 0.674 |
| HOMA-IR | 1.1 (0.9, 1.2) | 0.444 | 0.2 (-0.1, 0.5) | 0.283 |
| FBG (mmol/L) | 1.0 (0.8, 1.1) | 0.691 | -0.0 (-0.3, 0.2) | 0.799 |
| Triglyceride (mmol/L) | 1.0 (0.7, 1.4) | 0.972 | -0.0 (-0.8, 0.7) | 0.914 |
| HDL (mmol/L) | 1.0 (0.1, 1.8) | 0.270 | -1.8 (-4.1, 0.5) | 0.138 |
| BMI | ||||
| <25kg/m2 | 1.0 | 1.0 | ||
| ≥25kg/m2 | 2.7 (1.1, 6.4) | 0.029 | 2.3 (1.7, 3.9) | 0.006 |
| IR | ||||
| Yes | 1.0 | 1.0 | ||
| No | 9.5 (3.3, 27.0) | <0.001 | 3.0 (1.5, 4.5) | <0.001 |
| MetS | ||||
| Yes | 1.0 | 1.0 | ||
| No | 4.9 (1.5, 15.5) | 0.008 | 6.2 (4.2, 8.2) | <0.001 |
| IR+ and MetS+ | ||||
| IR- and MetS- | 1.0 | 1.0 | ||
| IR+ or MetS+ | 7.2 (2.4,21.1) | <0.001 | 1.6 (0.2, 3.0) | 0.029 |
| IR+ and MetS+ | 21.0 (4.8.92.7) | <0.001 | 7.6 (5.5, 9.8) | <0.001 |
| Menstruation cycle | ||||
| Regular | 1.0 | 1.0 | ||
| Irregular | 1.2 (0.6, 2.6) | 0.640 | 1.1 (-0.5, 2.7) | 0.189 |
| Gestation | ||||
| No | 1.0 | 1.0 | ||
| Yes | 0.4 (0.2, 0.9) | 0.030 | -1.4 (-3.0, 0.2) | 0.083 |
| Parity | ||||
| No | 1.0 | 1.0 | ||
| Yes | 0.3 (0.1, 1.1) | 0.074 | -1.7 (-3.8, 0.4) | 0.107 |
| Family history | ||||
| No | 1.0 | 1.0 | ||
| Yes | 2.2 (0.6, 7.2) | 0.212 | 0.5 (-2.0, 3.1) | 0.688 |
| Hypertension | ||||
| No | 1.0 | 1.0 | ||
| Yes | 2.0 (0.5, 8.6) | 0.337 | 1.9 (-1.2, 5.0) | 0.231 |
| Diabetes | ||||
| No | 1.0 | 1.0 | ||
| Yes | 1.9 (0.7, 4.7) | 0.180 | 2.8 (1.1, 4.7) | 0.004 |
| PCOS | ||||
| No | 1.0 | 1.0 | ||
| Yes | 0.7 (0.3, 1.5) | 0.325 | -1.2 (-2.8, 0.4) | 0.152 |
| Histological type | ||||
| AEH | 1.0 | 1.0 | ||
| G1EA | 3.5 (1.5, 7.9) | 0.003 | 2.5 (1.5, 4.0) | 0.002 |
| Progestin type | ||||
| MPA250mg | 1.0 | 1.0 | ||
| MPA500mg | 1.0 (0.3, 3.5) | 0.967 | -1.2 (-3.7, 1.3) | 0.347 |
| MA | 2.5 (0.8, 7.3) | 0.103 | 0.4 (-1.8, 2.7) | 0.717 |
| GnRH | 0.4 (0.0, 3.2) | 0.365 | -2.1 (-5.4, 1.2) | 0.217 |
| ≥2 types | 1.6 (0.3, 8.0) | 0.539 | 2.9 (-0.4, 6.2) | 0.088 |
| Time to CR (month) | ||||
| <3 | 1.0 | 1.0 | ||
| 3-6 | 1.1 (0.6, 2.0) | 0.621 | 0.8 (0.5, 1.5) | 0.518 |
| >6 | 2.0 (0.8, 5.1) | 0.375 | 0.9 (0.4, 1.8) | 0.857 |
| Maintenance treatment after primary CR | ||||
| No | 1.0 | 1.0 | ||
| Yes | 0.3 (0.1, 0.6) | 0.005 | 0.4 (0.1, 0.7) | 0.016 |
SD, standard deviation; BMI, body mass index; HOMA-IR, homeostasis model assessment of insulin resistance-insulin resistance; HDL, high-density lipoprotein; RCR time, complete remission time after recurrence; RFS, recurrence-free survival; IR, insulin resistance; MetS, metabolic syndrome; PCOS, polycystic ovarian syndrome; AEH, atypical endometrial hyperplasia; CR, complete remission.